Skip to main content
⌘K
·
Launch Terminal
Launch Terminal
Home
SEC Filings
Home
SEC Filings
Filings
Filing Date
Form Type
Company
Description
AI
Link
Learn
MCP
API
Cookie Preferences
INOD · Form 4 · FORLENZA LOUISE C – INNODATA INC | Signal8
Material events
Financial results
Capital raises
Insider transactions
Fund filings
Advanced filters
Any time
Sort
Filings
Filing Date
Form Type
Company
Description
AI
Link
Browse AI-analysed SEC filings
Page 1 of 74 · 7,311 total
CANF: 6-K · clinical trial
CANF · 6-K · 2026-10-26
VZ: 8-K · earnings release
VZ · 8-K · 2026-10-26
HBT: 8-K · earnings release
HBT · 8-K · 2026-10-26
GETY: 8-K · bankruptcy
GETY · 8-K · 2026-10-26
AZO: 8-K · leadership change
AZO · 8-K · 2026-10-26
INMD: 6-K · acquisition merger
INMD · 6-K · 2026-10-26
ZEOX: 8-K · material agreement
ZEOX · 8-K · 2026-10-26
LAWR: 6-K · delisting
LAWR · 6-K · 2026-10-26
FURY: 6-K · clinical trial
FURY · 6-K · 2026-10-26
LKFN: 8-K · earnings release
LKFN · 8-K · 2026-10-26
GSK: 6-K · clinical trial
GSK · 6-K · 2026-10-26
OVV: 8-K · acquisition merger
OVV · 8-K · 2026-10-26
HDB: 6-K · other
HDB · 6-K · 2026-10-26
BNTX: 6-K · clinical trial
BNTX · 6-K · 2026-10-26
DEA: 8-K · earnings release
DEA · 8-K · 2026-10-26
SNY: 6-K · other
SNY · 6-K · 2026-10-26
JMIA: 6-K · leadership change
JMIA · 6-K · 2026-10-26
ATMU: 8-K · leadership change
ATMU · 8-K · 2026-10-26
KKR: 8-K · leadership change
KKR · 8-K · 2026-10-26
MMYT: 6-K · earnings release
MMYT · 6-K · 2026-10-26
GSK: 6-K · clinical trial
GSK · 6-K · 2026-10-26
MRT: 6-K · litigation
MRT · 6-K · 2026-10-26
CCHH: 6-K · ticker change
CCHH · 6-K · 2026-10-26
BNTX: 6-K · clinical trial
BNTX · 6-K · 2026-10-26
HCM: 6-K · clinical trial
HCM · 6-K · 2026-10-26
RDY: 6-K · earnings release
RDY · 6-K · 2026-10-26
PUK: 6-K · share repurchase
PUK · 6-K · 2026-10-26
RDY: 6-K · periodic report
RDY · 6-K · 2026-10-26
EQT: 8-K · acquisition merger
EQT · 8-K · 2026-10-26
ZTO: 6-K · share repurchase
ZTO · 6-K · 2026-10-26
AGLY: 10-Q · periodic report
AGLY · 10-Q · 2026-10-26
YI: 6-K · acquisition merger
YI · 6-K · 2026-10-26
KB: 6-K · ownership disclosure
KB · 6-K · 2026-10-26
IBN: 6-K · other
IBN · 6-K · 2026-10-26
BEKE: 6-K · share repurchase
BEKE · 6-K · 2026-10-26
ELME: 8-K · delisting
ELME · 8-K · 2026-10-26
CX: 6-K · earnings release
CX · 6-K · 2026-10-26
ZH: 6-K · share repurchase
ZH · 6-K · 2026-10-26
KB: 6-K · share repurchase
KB · 6-K · 2026-10-26
LADR: 10-Q · periodic report
LADR · 10-Q · 2026-10-23
LICN: 6-K · reverse split
LICN · 6-K · 2026-10-23
MMYT: 6-K · earnings release
MMYT · 6-K · 2026-10-26
MDCX: 424B3 · prospectus supplement
MDCX · 424B3 · 2026-10-23
ESLT: 6-K · material agreement
ESLT · 6-K · 2026-10-26
UFG: 6-K · offering registration
UFG · 6-K · 2026-10-23
NBP: 6-K · clinical trial
NBP · 6-K · 2026-10-26
NBTX: 6-K · clinical trial
NBTX · 6-K · 2026-10-26
IBN: 6-K · periodic report
IBN · 6-K · 2026-10-26
BORR: 6-K · other
BORR · 6-K · 2026-10-26
PBMLF: 6-K · offering registration
PBMLF · 6-K · 2026-10-24
CETI: 8-K · material agreement
CETI · 8-K · 2026-10-24
GGB: 6-K · other
GGB · 6-K · 2026-10-24
EARN: 424B3 · prospectus supplement
EARN · 424B3 · 2026-10-24
XPON: S-3 · shelf registration
XPON · S-3 · 2026-10-23
CHAR: 8-K · delisting
CHAR · 8-K · 2026-10-23
HSCS: SCHEDULE 13D/A · ownership disclosure
HSCS · SCHEDULE 13D/A · 2026-10-24
BRR: SCHEDULE 13D/A · ownership disclosure
BRR · SCHEDULE 13D/A · 2026-10-23
INV: 8-K · delisting
INV · 8-K · 2026-10-23
ANDE: 8-K · leadership change
ANDE · 8-K · 2026-10-23
APXC: 6-K · prospectus supplement
APXC · 6-K · 2026-10-23
HKIT: 6-K · periodic report
HKIT · 6-K · 2026-10-23
IMRN: 6-K · offering registration
IMRN · 6-K · 2026-10-23
FFAI: S-3/A · shelf registration
FFAI · S-3/A · 2026-10-23
IMRN: 424B5 · prospectus supplement
IMRN · 424B5 · 2026-10-23
EDSA: 8-K · leadership change
EDSA · 8-K · 2026-10-23
XXII: 424B5 · prospectus supplement
XXII · 424B5 · 2026-10-23
EVTV: 8-K · debt financing
EVTV · 8-K · 2026-10-23
NTCL: 6-K · reverse split
NTCL · 6-K · 2026-10-23
AMSS: 8-K · amendment
AMSS · 8-K · 2026-10-23
PHGE: 8-K · offering registration
PHGE · 8-K · 2026-10-23
HTLM: 6-K · foreign private issuer
HTLM · 6-K · 2026-10-23
TDY: 10-Q · periodic report
TDY · 10-Q · 2026-10-23
TRAW: 8-K · material agreement
TRAW · 8-K · 2026-10-23
APXC: 6-K · offering registration
APXC · 6-K · 2026-10-23
ONFO: S-1 · offering registration
ONFO · S-1 · 2026-10-23
RMXI: 8-K · debt financing
RMXI · 8-K · 2026-10-23
TGL: 8-K · material agreement
TGL · 8-K · 2026-10-23
MDCX: 8-K · delisting
MDCX · 8-K · 2026-10-23
WULF: 8-K · debt financing
WULF · 8-K · 2026-10-23
UFG: 424B5 · prospectus supplement
UFG · 424B5 · 2026-10-23
IPW: S-3/A · shelf registration
IPW · S-3/A · 2026-10-23
BURU: 424B3 · prospectus supplement
BURU · 424B3 · 2026-10-23
C: 424B3 · prospectus supplement
C · 424B3 · 2026-10-23
CPAC: 6-K · acquisition merger
CPAC · 6-K · 2026-10-23
PINE: 8-K · offering registration
PINE · 8-K · 2026-10-23
XPON: 8-K · material agreement
XPON · 8-K · 2026-10-23
PREM: 8-K · leadership change
PREM · 8-K · 2026-10-23
FPH: 10-Q · periodic report
FPH · 10-Q · 2026-10-23
TAOX: S-3/A · shelf registration
TAOX · S-3/A · 2026-10-23
BTOG: 6-K · reverse split
BTOG · 6-K · 2026-10-23
STFS: 20-F · periodic report
STFS · 20-F · 2026-10-23
MCFT: 424B3 · prospectus supplement
MCFT · 424B3 · 2026-10-23
MCRP: 6-K · debt financing
MCRP · 6-K · 2026-10-23
GRDX: 8-K · leadership change
GRDX · 8-K · 2026-10-23
INSW: 8-K · material agreement
INSW · 8-K · 2026-10-23
ARTC: 8-K · leadership change
ARTC · 8-K · 2026-10-23
FUSE: 8-K · material agreement
FUSE · 8-K · 2026-10-23
AQB: 424B3 · prospectus supplement
AQB · 424B3 · 2026-10-23
DRI: 8-K · debt financing
DRI · 8-K · 2026-10-23
GGRP: S-3 · shelf registration
GGRP · S-3 · 2026-10-23
1
2
3
4
8
12
16
20
24
28
32
36
40
44
48
52
56
60
64
68
72
74
Next ›
